Medication Monitor



Generic Name (Trade Name—Company)
Notes
April 25, 2019

Risankizumab-rzaa

(Skyrizi—Boehringer/AbbVie)
IL-23 inhibitor approved for moderate to severe plaque psoriasis

FDA approved risankizumab-rzaa, an interleukin-23 (IL-23) inhibitor, to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. 

In clinical trials, risankizumab produced high rates of durable skin clearance, with most participants (82% and 81%) achieving a 90% skin clearance (PASI 90) at 1 year, and the majority (56% and 60%) achieving complete skin clearance (PASI 100).

The recommended dose is 150 mg administered by two S.C. injections every 12 weeks following two initiation doses at weeks 0 and 4. The drug can be administered in the office or by self-injection after training.

The most common adverse events associated with risankizumab are upper respiratory infections, headache, fatigue, injection-site reactions, and tinea infections. The drug requires an initial evaluation for tuberculosis (TB) prior to starting treatment, and patients are instructed to report signs and symptoms of infection.